{ "schemaVersion": 2, "eyebrow": "Endocrinology", "title": "Type 2 Diabetes", "summary": "Type 2 diabetes management should pair individualized glycemic targets with early selection of therapies that reduce cardiovascular, heart failure, kidney, weight, and hypoglycemia risk—not simply A1C. Reassess medication effectiveness, safety, affordability, and treatment burden every 3–6 months.", "seoDescription": "Evidence-based diagnosis, glycemic goals, and medication selection for adults with type 2 diabetes, including cardiorenal risk reduction.", "clinicalQuestion": "How should clinicians individualize glycemic monitoring and select glucose-lowering therapy for adults with type 2 diabetes?", "specialty": "Endocrinology", "audience": "U.S. physicians and medical trainees", "tags": [ "type 2 diabetes", "A1C goals", "SGLT2 inhibitors", "GLP-1 receptor agonists", "metformin", "insulin initiation", "cardiorenal risk reduction" ], "keyTakeaways": [ "For many nonpregnant adults, an A1C goal <7%, preprandial glucose 80–130 mg/dL, and peak postprandial glucose <180 mg/dL are appropriate; relax goals when treatment burden or hypoglycemia risk outweighs benefit. [23]", "In type 2 diabetes with ASCVD, heart failure, or CKD, use an SGLT2 inhibitor and/or GLP-1 receptor agonist with demonstrated benefit irrespective of A1C or metformin use. [20]", "Initiate insulin for symptomatic hyperglycemia, catabolism, A1C >10%, or glucose ≥300 mg/dL; otherwise, a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist is generally preferred before insulin when insulin deficiency is not evident. [20]", "Prevent avoidable harm by reassessing insulin, sulfonylurea, or meglitinide doses when adding lower-hypoglycemia-risk therapy and by screening for financial barriers. [20]" ], "sections": [ { "id": "treatment-priorities", "eyebrow": "Clinical approach", "heading": "Choose therapy by organ risk and treatment burden", "intro": "A1C reduction remains important, but drug choice should address the complication most likely to affect the patient next.", "paragraphs": [ "Use shared decision-making to select therapy based on glucose-lowering efficacy, weight effects, ASCVD, heart failure, CKD, hypoglycemia risk, adverse effects, regimen complexity, access, and cost. Review the medication plan and medication-taking behavior every 3–6 months; do not delay intensification or deintensification when individualized goals are not met. [20]", "For adults without established ASCVD, heart failure, or CKD, metformin remains a common foundational therapy because it is effective, inexpensive, weight neutral, and rarely causes hypoglycemia. Gastrointestinal effects can often be mitigated by slow titration or extended-release formulation. Metformin may be used with eGFR ≥30 mL/min/1.73 m²; do not initiate it below eGFR 45 mL/min/1.73 m², reduce dose below 45 mL/min/1.73 m², and stop below 30 mL/min/1.73 m². Periodically consider vitamin B12 assessment, particularly with neuropathy or long-term exposure. [20]" ], "bullets": [ "Avoid concurrent DPP-4 inhibitor and GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist therapy because it adds no meaningful glucose lowering. [20]", "When initiating a drug that lowers glucose without intrinsically causing hypoglycemia, reassess insulin, sulfonylurea, and meglitinide doses to reduce hypoglycemia and treatment burden. [20]", "Assess financial barriers routinely; lower-cost options include metformin, sulfonylureas, thiazolidinediones, and human insulin, but these trade lower acquisition cost for greater risks of hypoglycemia, weight gain, or other adverse effects. [20]" ], "subsections": [], "table": { "caption": "Organ-directed treatment priorities in type 2 diabetes. [20]", "columns": [ "Clinical phenotype", "Preferred glucose-lowering strategy", "Key implementation point" ], "rows": [ [ "Established ASCVD or high ASCVD risk", "GLP-1 receptor agonist and/or SGLT2 inhibitor with demonstrated cardiovascular benefit. [20]", "Use irrespective of baseline A1C, A1C goal, or metformin use. [20]" ], [ "Heart failure, reduced or preserved ejection fraction", "SGLT2 inhibitor. [20]", "Recommended for glycemic management and prevention of heart failure hospitalization irrespective of A1C. [20]" ], [ "CKD with eGFR 20–60 mL/min/1.73 m² and/or albuminuria", "SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated benefit. [20]", "SGLT2 inhibitor glycemic effect declines below eGFR 45 mL/min/1.73 m², but cardiorenal benefit remains a central reason for use. [20]" ], [ "Advanced CKD, eGFR <30 mL/min/1.73 m²", "GLP-1 receptor agonist preferred for glycemic management. [20]", "Lower hypoglycemia risk and cardiovascular event reduction support preference. [20]" ], [ "Obesity with need for glucose lowering", "Prioritize weight-lowering agents when appropriate; tirzepatide and semaglutide have highest glucose- and weight-lowering efficacy among listed agents. [20]", "Avoid unnecessary insulin, sulfonylurea, or thiazolidinedione exposure when alternatives can meet goals. [20]" ] ] } }, { "id": "glycemic-targets-monitoring", "eyebrow": "Monitoring", "heading": "Set glycemic goals that can be attained safely", "intro": "Targets should change with life expectancy, comorbidity, hypoglycemia risk, and patient priorities.", "paragraphs": [ "For many nonpregnant adults, target A1C <7%, preprandial capillary glucose 80–130 mg/dL, and peak postprandial glucose <180 mg/dL measured 1–2 hours after beginning a meal. Lower A1C can be reasonable when achieved without frequent or severe hypoglycemia or excessive burden; less stringent goals may be appropriate when harms exceed expected benefit. [23]", "Measure A1C at least twice yearly when stable and at goal; assess about every 3 months with recent treatment change, lack of goal attainment, frequent severe dysglycemia, or changing health status. Use CGM metrics, BGM, fructosamine, or glycated albumin when A1C is unreliable because of altered red-cell turnover, hemoglobin disorders, transfusion, end-stage kidney disease, or pregnancy. [23]", "For CGM users, obtain at least 14 days of data with ≥70% active wear when using patterns for clinical decisions. Typical goals for many adults are time in range 70–180 mg/dL >70%, time below 70 mg/dL <4%, time below 54 mg/dL <1%, time above 180 mg/dL <25%, and time above 250 mg/dL <5%. [23]" ], "bullets": [ "Assess A1C together with CGM or BGM when glycemic variability, hypoglycemia, or A1C–glucose discordance is likely. [23]", "Deintensify insulin, sulfonylureas, or meglitinides, or substitute lower-hypoglycemia-risk therapy, when hypoglycemia risk is high or treatment burdens exceed benefit. [23]", "Any level 2 hypoglycemia (<54 mg/dL) or level 3 event requiring assistance should trigger prompt treatment-plan reevaluation. [23]" ], "subsections": [], "table": { "caption": "Practical glycemic monitoring targets for many nonpregnant adults. [23]", "columns": [ "Measure", "Usual target", "Action when off target" ], "rows": [ [ "A1C", "<7% for many adults. [23]", "Individualize upward or downward according to safety, life expectancy, comorbidity, and treatment burden. [23]" ], [ "Preprandial capillary glucose", "80–130 mg/dL. [23]", "Review basal therapy, meal timing, adherence, and hypoglycemia exposure before titration. [23]" ], [ "Peak postprandial capillary glucose", "<180 mg/dL 1–2 hours after meal start. [23]", "Address meal-related hyperglycemia when A1C remains above goal despite preprandial targets. [23]" ], [ "CGM time in range, 70–180 mg/dL", ">70% for most adults; >50% for older adults. [23]", "Prioritize reduction of time below range before pursuing tighter hyperglycemia targets. [23]" ] ] } }, { "id": "medication-selection", "eyebrow": "Pharmacotherapy", "heading": "Use insulin selectively and safely", "intro": "Insulin is essential in severe hyperglycemia or insulin deficiency, but not automatically the next injectable option.", "paragraphs": [ "Consider insulin regardless of current therapy when symptoms of hyperglycemia or catabolic features are present, or when A1C exceeds 10% or blood glucose is ≥300 mg/dL. In adults without evidence of insulin deficiency, a GLP-1 receptor agonist, including a dual GIP/GLP-1 receptor agonist, is preferred to insulin because of favorable hypoglycemia and weight effects. [20]", "When basal insulin is required, a typical starting dose is 0.1–0.2 units/kg/day with individualized titration over days to weeks. If fasting glucose is controlled but A1C remains elevated, evaluate for postprandial hyperglycemia or overbasalization rather than simply escalating basal insulin. Signals include bedtime-to-morning or preprandial-to-postprandial differentials of at least 50 mg/dL, hypoglycemia, or high glycemic variability. [20]", "If basal insulin alone is insufficient, add a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist before prandial insulin when feasible. If prandial insulin is needed, begin with 4 units or 10% of the basal dose at the largest meal or meal with the greatest postprandial excursion, then intensify according to glucose data. [20]" ], "bullets": [ "Long-acting insulin analogs reduce nocturnal and level 2 hypoglycemia compared with NPH insulin; degludec or glargine U-300 can reduce nocturnal hypoglycemia relative to glargine U-100. [20]", "Continue metformin, SGLT2 inhibitors, and GLP-1 receptor agonists during insulin intensification unless contraindicated or not tolerated, because they may preserve metabolic, cardiorenal, or weight benefits. [20]", "Limit or stop sulfonylureas, meglitinides, and DPP-4 inhibitors during complex insulin intensification when they add little benefit or increase hypoglycemia and weight burden. [20]" ], "subsections": [], "table": { "caption": "Insulin escalation decisions in type 2 diabetes. [20]", "columns": [ "Situation", "Preferred next step", "Safety issue" ], "rows": [ [ "Symptomatic hyperglycemia, catabolism, A1C >10%, or glucose ≥300 mg/dL", "Initiate insulin; simplify later if glucose toxicity resolves and noninsulin therapy becomes adequate. [20]", "Provide education on glucose monitoring, sick-day management, and hypoglycemia prevention. [20]" ], [ "Insulin-naive patient requiring basal insulin", "Start basal insulin 0.1–0.2 units/kg/day and titrate. [20]", "Avoid excessive basal escalation when fasting glucose is controlled but A1C remains elevated. [20]" ], [ "Basal insulin optimized but postprandial hyperglycemia persists", "Add GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist if not already used; otherwise add prandial insulin. [20]", "Reassess basal dose when substantial prandial insulin is added to avoid hypoglycemia. [20]" ], [ "Need for first prandial dose", "Start 4 units or 10% of basal insulin at largest meal. [20]", "Use BGM or CGM patterns to titrate; coordinate insulin with food intake. [20]" ] ] } }, { "id": "safety-and-sick-day-management", "eyebrow": "Safety", "heading": "Prevent hypoglycemia and ketoacidosis", "intro": "Medication safety planning is most important when insulin, secretagogues, or SGLT inhibition are used.", "paragraphs": [ "Review hypoglycemia at every encounter in people using insulin, sulfonylureas, or meglitinides. High-risk features include recent level 2 or 3 hypoglycemia, impaired awareness, intensive insulin therapy, end-stage kidney disease, cognitive impairment, food insecurity, low income, housing insecurity, and fasting. CGM is recommended for individuals at high hypoglycemia risk. [23]", "Treat conscious hypoglycemia at glucose <70 mg/dL with fast-acting carbohydrate, typically 15 g, and recheck after 15 minutes. Avoid high-fat or high-protein foods for initial rescue. Prescribe glucagon for all people taking insulin or at high hypoglycemia risk; ready-to-use intranasal or injectable products are preferred because they do not require reconstitution. [23]", "SGLT2 inhibitors can precipitate ketoacidosis with lower-than-expected glucose. In type 2 diabetes, reported DKA incidence is 0.6–4.9 events per 1,000 patient-years; risk factors include carbohydrate restriction, prolonged fasting, dehydration, excess alcohol, acute illness, and insulin deficiency. Educate patients to recognize nausea, vomiting, abdominal pain, malaise, and dyspnea; assess ketones despite modest glucose elevation when symptoms occur. [20][23]" ], "bullets": [ "SGLT2 inhibitors are not approved for type 1 diabetes because DKA risk is substantially increased. [20]", "For planned surgery, discontinue SGLT2 inhibitors 3–4 days beforehand; FDA labeling cited in hospital guidance specifies 4 days for ertugliflozin. [21]", "During illness or fasting, insulin-treated patients should not omit basal insulin; intensify glucose and ketone monitoring when clinically indicated. [23]" ], "subsections": [], "table": { "caption": "High-yield safety triggers in diabetes treatment. [20][23]", "columns": [ "Trigger", "Immediate clinical response", "Why it matters" ], "rows": [ [ "Level 2 hypoglycemia, glucose <54 mg/dL", "Reevaluate and deintensify or modify hypoglycemia-causing therapy. [23]", "Signals high risk for recurrent severe hypoglycemia. [23]" ], [ "Illness, prolonged fasting, vomiting, or carbohydrate restriction while using SGLT2 inhibitor", "Assess for ketonemia or ketonuria if symptoms suggest acidosis; stop the agent if ketoacidosis is suspected and treat promptly. [23]", "Euglycemic or mildly hyperglycemic DKA can delay recognition. [23]" ], [ "Impaired hypoglycemia awareness", "Temporarily relax glycemic goals, provide structured education, and use CGM when appropriate. [23]", "Avoidance of recurrent hypoglycemia can improve awareness. [23]" ], [ "Hospitalization for noncritical illness with persistent glucose ≥180 mg/dL", "Initiate or intensify insulin and/or other therapy after confirmation on two occasions within 24 hours. [21]", "Hospital hyperglycemia is associated with adverse outcomes. [21]" ] ] } }, { "id": "inpatient-care", "eyebrow": "Acute care", "heading": "Manage hospitalized hyperglycemia with scheduled therapy", "intro": "Inpatient regimens should match nutritional intake and diabetes type.", "paragraphs": [ "For noncritically ill hospitalized adults, initiate or intensify therapy for persistent glucose ≥180 mg/dL confirmed twice within 24 hours. A glucose goal of 100–180 mg/dL is recommended in noncritical care, while 140–180 mg/dL is recommended for most critically ill adults after treatment begins. [21]", "Use basal insulin or basal-plus correction insulin for patients with poor intake or NPO status; use basal, prandial, and correction insulin for those eating reliably. Correction-only insulin without basal insulin is discouraged, particularly in type 1 diabetes, in whom basal insulin must continue even while NPO. [21]", "For type 2 diabetes hospitalized with heart failure, initiate or continue an SGLT2 inhibitor during hospitalization and at discharge after recovery from acute illness when no contraindication exists. Avoid SGLT2 inhibitors during severe illness, ketonemia or ketonuria, prolonged fasting, and surgical procedures. [21]" ], "bullets": [ "Measure A1C on admission in people with diabetes or glucose >140 mg/dL if no result is available from the previous 3 months. [21]", "If using a personal CGM or automated insulin delivery system in hospital, continue only when clinically appropriate, institutional protocols and trained staff are available, and confirmatory point-of-care glucose is used for insulin dosing and hypoglycemia assessment. [21]", "Begin discharge planning at admission; arrange follow-up within 1 month, or in 1–2 weeks when medications changed or glycemia remains unstable. [21]" ], "subsections": [], "table": { "caption": "Hospital glucose-management priorities. [21]", "columns": [ "Clinical setting", "Glycemic goal", "Preferred regimen" ], "rows": [ [ "Noncritical care", "100–180 mg/dL. [21]", "Basal plus correction if poor intake/NPO; basal-prandial-correction if eating. [21]" ], [ "Critical care", "140–180 mg/dL for most patients. [21]", "Validated intravenous insulin protocol when indicated. [21]" ], [ "Type 1 diabetes, including NPO status", "Individualize while avoiding hypoglycemia and hyperglycemia. [21]", "Continue basal insulin plus correction; add prandial insulin when eating. [21]" ], [ "Transition from intravenous insulin", "Prevent rebound hyperglycemia. [21]", "Administer subcutaneous basal insulin 2 hours before discontinuing infusion. [21]" ] ] } } ], "faq": [ { "question": "When should insulin be initiated in type 2 diabetes?", "answer": "Consider insulin for symptomatic hyperglycemia, catabolic features, A1C >10%, or glucose ≥300 mg/dL. In the absence of insulin deficiency, GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist therapy is generally preferred before insulin. [20]" }, { "question": "Should SGLT2 inhibitors or GLP-1 receptor agonists be used when A1C is already at target?", "answer": "Yes, when type 2 diabetes coexists with ASCVD, heart failure, or CKD and the selected agent has demonstrated relevant benefit. These therapies are recommended independent of A1C and metformin use for cardiorenal risk reduction. [20]" }, { "question": "How often should A1C be checked in stable type 2 diabetes?", "answer": "Assess at least twice yearly when glycemia is stable and at goal. Check approximately every 3 months when goals are unmet, therapy changes, severe dysglycemia occurs, or health status changes. [23]" }, { "question": "What should prompt deintensification of diabetes therapy?", "answer": "Level 2 or 3 hypoglycemia, high hypoglycemia risk, excessive treatment burden, intolerance, new contraindications, or a change in goals or life expectancy should prompt reassessment and possible deintensification. [23][20]" }, { "question": "What is the key concern with SGLT2 inhibitors during illness or surgery?", "answer": "Euglycemic DKA. Hold SGLT2 inhibitors during severe illness, prolonged fasting, or surgery; discontinue 3–4 days before planned procedures. Evaluate ketones if acidosis symptoms occur despite nonsevere hyperglycemia. [21][23]" } ], "references": [ { "number": 1, "title": "FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes | FDA", "detail": "www.fda.gov", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 2, "title": "GLUCOPHAGE (metformin hydrochloride) Tablets", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 3, "title": "FDA Approves First Generic Dapagliflozin Tablets", "detail": "www.fda.gov", "url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-approves-first-generic-dapagliflozin-tablets", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 4, "title": "TRESIBA® (insulin degludec) injection, for subcutaneous use", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203314s018s020lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 5, "title": "3855986 This label may not be the latest approved by FDA ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204042s013lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 6, "title": "XIGDUO XR (dapagliflozin and metformin HCl extended ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205649s008lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 7, "title": "Frequently Asked Questions about Labeling for Prescription Medicines | FDA", "detail": "www.fda.gov", "url": "https://www.fda.gov/drugs/fdas-labeling-resources-human-prescription-drugs/frequently-asked-questions-about-labeling-prescription-medicines", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 8, "title": "https://nctr-crs.fda.gov/fdalabel/services/spl/ ...", "detail": "nctr-crs.fda.gov", "url": "https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/02857195-33e9-4c1f-9e5f-7cc62f283649/spl-doc", "authors": "nctr-crs.fda.gov", "host": "nctr-crs.fda.gov" }, { "number": 9, "title": "Diabetes Medicines", "detail": "www.fda.gov", "url": "https://www.fda.gov/files/for%20consumers/published/Diabetes-Medicines.pdf", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 10, "title": "Navigating the Complexities of Diabetes Management - Annals of Internal Medicine: Fresh Look Blog", "detail": "freshlook.annals.org", "url": "https://freshlook.annals.org/2025/08/navigating-complexities-of-diabetes.html", "authors": "freshlook.annals.org", "host": "freshlook.annals.org" }, { "number": 11, "title": "Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M16-1860", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 12, "title": "Newer Pharmacologic Treatments in Adults With Type 2 ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M23-2788", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 13, "title": "Diagnosis and Management of Diabetes: Synopsis of the ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M15-3016", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 14, "title": "Pharmacologic Approaches to Glycemic Treatment of Type ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M20-2470", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 15, "title": "Systematic review of clinical practice guidelines to identify ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0168822720307890", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 16, "title": "Drug Dosing Recommendations for All Patients: A Roadmap ...", "detail": "ascpt.onlinelibrary.wiley.com", "url": "https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1923", "authors": "ascpt.onlinelibrary.wiley.com", "host": "ascpt.onlinelibrary.wiley.com" }, { "number": 17, "title": "2024 CPDD Abstract Booklet - 2024 - Wiley Online Library", "detail": "accp1.onlinelibrary.wiley.com", "url": "https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/cpdd.1459", "authors": "accp1.onlinelibrary.wiley.com", "host": "accp1.onlinelibrary.wiley.com" }, { "number": 18, "title": "Type 2 diabetes in adults: management | Guidance", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng28", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 19, "title": "10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026", "detail": "www.ccjm.org", "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc26-S010&link_type=DOI", "authors": "www.ccjm.org", "host": "www.ccjm.org" }, { "number": 20, "title": "9. Pharmacologic Approaches to Glycemic Treatment", "detail": "www.ccjm.org", "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc25-S009&link_type=DOI", "authors": "www.ccjm.org", "host": "www.ccjm.org" }, { "number": 21, "title": "16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024", "detail": "www.ccjm.org", "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc24-S016&link_type=DOI", "authors": "www.ccjm.org", "host": "www.ccjm.org" }, { "number": 22, "title": "Initial medicines | Type 2 diabetes in adults: management | Guidance | NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng28/chapter/Initial-medicines", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 23, "title": "6. Glycemic Goals and Hypoglycemia: Standards of Care in ...", "detail": "www.ccjm.org", "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc25-S006&link_type=DOI", "authors": "www.ccjm.org", "host": "www.ccjm.org" }, { "number": 24, "title": "Tests for Screening and Diagnosis of Type 2 Diabetes", "detail": "diabetesjournals.org", "url": "https://diabetesjournals.org/clinical/article/27/4/132/1673/Tests-for-Screening-and-Diagnosis-of-Type-2", "authors": "diabetesjournals.org", "host": "diabetesjournals.org" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes | FDA", "detail": "www.fda.gov", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "drugs known to cause hypoglycemia including insulin and sulfonylurea, renal impairment or kidney failure, hypersensitivity and acute gallbladder disease. The most common side effects reported in the clinical trials for liraglutide injection include nausea, diarrhea, vomiting, decreased appetite, dys", "score": 0.55623144 }, { "number": 2, "title": "GLUCOPHAGE (metformin hydrochloride) Tablets", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. Assess renal function more frequently in elderly patients (see WARNINGS, PRECAUTIONS, and DO", "score": 0.45653152 }, { "number": 3, "title": "FDA Approves First Generic Dapagliflozin Tablets", "detail": "www.fda.gov", "url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-approves-first-generic-dapagliflozin-tablets", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "Type 2 diabetes is a chronic condition that occurs when the body does not use insulin well and cannot keep blood sugar at normal levels. It develops over many years and is usually diagnosed in adults. According to the Centers for Disease Control and Prevention, more than 40 million Americans have di", "score": 0.43036336 }, { "number": 4, "title": "TRESIBA® (insulin degludec) injection, for subcutaneous use", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203314s018s020lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "Degludec subcutaneously once daily at any time of day.  In pediatric patients inject Insulin Degludec subcutaneously once daily at the same time every day.  Individualize and titrate the dose of Insulin Degludec based on the patient’s metabolic needs, blood glucose monitoring results, and glycemic", "score": 0.42076674 }, { "number": 5, "title": "3855986 This label may not be the latest approved by FDA ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204042s013lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE INVOKANA® (canagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14)]. Limitation of Use INVOKANA is not recommended in patients with type 1 diabetes me", "score": 0.41023695 }, { "number": 6, "title": "XIGDUO XR (dapagliflozin and metformin HCl extended ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205649s008lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "adverse reactions related to reduced intravascular volume and renal function. (5.1, 6.1, 8.6)  Hepatic Impairment: Avoid use in patients with hepatic impairment. (8.7) See 17 for PATIENT COUNSELING INFORMATION and Medication Guide Revised: 7/2017 Reference ID: 4131552 This label may not be the late", "score": 0.35059974 }, { "number": 7, "title": "Frequently Asked Questions about Labeling for Prescription Medicines | FDA", "detail": "www.fda.gov", "url": "https://www.fda.gov/drugs/fdas-labeling-resources-human-prescription-drugs/frequently-asked-questions-about-labeling-prescription-medicines", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "| 2 Dosage and Administration | Recommended dosage (recommended dose and dosing frequency) Dosage range Recommended starting dosage and titration schedule Maximum recommended dosage Route(s) of administration Pre-medication or concomitant medicines Dosage modifications due to drug interaction", "score": 0.31028718 }, { "number": 8, "title": "https://nctr-crs.fda.gov/fdalabel/services/spl/ ...", "detail": "nctr-crs.fda.gov", "url": "https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/02857195-33e9-4c1f-9e5f-7cc62f283649/spl-doc", "authors": "nctr-crs.fda.gov", "host": "nctr-crs.fda.gov", "snippet": "... Information for Patients: In initiating treatment for type 2 diabetes, diet should be emphasized as the primary form of treatment.Read more", "score": 0.2769256 }, { "number": 9, "title": "Diabetes Medicines", "detail": "www.fda.gov", "url": "https://www.fda.gov/files/for%20consumers/published/Diabetes-Medicines.pdf", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "• Speak up. Tell someone about any problems you may be having with your medicines. Your doctor may change your medicine or give you tips to help you deal with the side effects.\n• Check the FDA website. You can find current safety information about your medicine at: www.fda.gov • Report serious probl", "score": 0.2497495 }, { "number": 10, "title": "Navigating the Complexities of Diabetes Management - Annals of Internal Medicine: Fresh Look Blog", "detail": "freshlook.annals.org", "url": "https://freshlook.annals.org/2025/08/navigating-complexities-of-diabetes.html", "authors": "freshlook.annals.org", "host": "freshlook.annals.org", "snippet": "1. Qaseem A, Obley AJ, Shamliyan T, et al; Clinical Guidelines Committee of the American College of Physicians. Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American College of Physicians. Ann Intern Med. 2024;177:658-666. [PMID: 38639546] doi:10.7326/", "score": 0.6672566 }, { "number": 11, "title": "Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M16-1860", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "by A Qaseem · 2017 · Cited by 293 — This evidence-based guideline from the American College of Physicians addresses oral pharmacologic treatment of type 2 diabetes in adults.", "score": 0.5372119 }, { "number": 12, "title": "Newer Pharmacologic Treatments in Adults With Type 2 ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M23-2788", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "by A Qaseem · 2024 · Cited by 131 — This ACP clinical guideline updates recommendations on newer pharmacologic treatments in adults with type 2 diabetes. It is based on 2", "score": 0.45551404 }, { "number": 13, "title": "Diagnosis and Management of Diabetes: Synopsis of the ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M15-3016", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "by JJ Chamberlain · 2016 · Cited by 870 — Type 2 Diabetes A patient-centered approach should guide the choice of pharmacologic agents (18). Providers should include colesevelam, and pramlintide, can be", "score": 0.25571102 }, { "number": 14, "title": "Pharmacologic Approaches to Glycemic Treatment of Type ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/M20-2470", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "by K Doyle-Delgado · 2020 · Cited by 163 — This synopsis focuses on guidance relating to the pharmacologic treatment of adults with type 2 diabetes. Recommendations address oral and", "score": 0.18559302 }, { "number": 15, "title": "Systematic review of clinical practice guidelines to identify ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0168822720307890", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Study design: Systematic Review.\n\n### Methodology\n\nClinical practice guidelines which focused on the management of type 2 diabetes mellitus in adults were included (n=35). Two independent reviewers utilised the Appraisal of Guidelines for Research and Evaluation tool (AGREE) II and a third reviewer ", "score": 0.62934244 }, { "number": 16, "title": "Drug Dosing Recommendations for All Patients: A Roadmap ...", "detail": "ascpt.onlinelibrary.wiley.com", "url": "https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1923", "authors": "ascpt.onlinelibrary.wiley.com", "host": "ascpt.onlinelibrary.wiley.com", "snippet": "May 26, 2020 — FDA has expected companies to perform PK studies in patients with either renal and/or hepatic impairment to determine if dosing adjustment is", "score": 0.5826579 }, { "number": 17, "title": "2024 CPDD Abstract Booklet - 2024 - Wiley Online Library", "detail": "accp1.onlinelibrary.wiley.com", "url": "https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/cpdd.1459", "authors": "accp1.onlinelibrary.wiley.com", "host": "accp1.onlinelibrary.wiley.com", "snippet": "Sep 1, 2024 — ... dosing information in adult and pediatric with renal impairment ... Drug Administration Between 2017 & 2023 to Treat Type 2 Diabetes. T ...Read more", "score": 0.42133808 }, { "number": 18, "title": "Type 2 diabetes in adults: management | Guidance", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng28", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "You are here:\n\n# Type 2 diabetes in adults: management\n\n## Overview\n\nThis guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-t", "score": 0.6504012 }, { "number": 19, "title": "10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026", "detail": "www.ccjm.org", "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc26-S010&link_type=DOI", "authors": "www.ccjm.org", "host": "www.ccjm.org", "snippet": "2021\n\n;\n\n385\n\n:\n\n1451\n\n–\n\n1461\n\nGoogle Scholar\n\n243.\n\nKezerashvili\n\nA\n\n, \n\nMarzo\n\nK\n\n, \n\nDe Leon\n\nJ\n\n. \n\nBeta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it “ok” to discontinue?\n\nCurr Cardiol Rev\n\n2012\n\n;\n\n8\n\n:\n\n77\n\n–\n\n84\n\nGoogle Scholar\n\n244.\n", "score": 0.36351183 }, { "number": 20, "title": "9. Pharmacologic Approaches to Glycemic Treatment", "detail": "www.ccjm.org", "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc25-S009&link_type=DOI", "authors": "www.ccjm.org", "host": "www.ccjm.org", "snippet": ":\n\n1569\n\n–\n\n1577\n\nGoogle Scholar\n\nCrossref\n\nSearch ADS\n\nPubMed\n\n136.\n\nKidney Disease: Improving Global Outcomes Diabetes Work Group\n\n. \n\nKDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease\n\n. \n\nKidney Int\n\n2022\n\n;\n\n102\n\n:\n\nS1\n\n–\n\nS127\n\nCrossref\n\nSearch ADS\n\nPubMe", "score": 0.3594546 }, { "number": 21, "title": "16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024", "detail": "www.ccjm.org", "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc24-S016&link_type=DOI", "authors": "www.ccjm.org", "host": "www.ccjm.org", "snippet": "1.\n\nSeisa\n\nMO\n\n, \n\nSaadi\n\nS\n\n, \n\nNayfeh\n\nT\n\n, _et al_. \n\nA systematic review supporting the Endocrine Society clinical practice guideline for the management of hyperglycemia in adults hospitalized for noncritical illness or undergoing elective surgical procedures\n\n. \n\nJ Clin Endocrinol Metab\n\n2022\n\n", "score": 0.32498527 }, { "number": 22, "title": "Initial medicines | Type 2 diabetes in adults: management | Guidance | NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng28/chapter/Initial-medicines", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "Subcutaneous semaglutide (Ozempic), up to 1 mg once a week, also had the best clinical results. Evidence showed that it made a clinically important reduction to the person's:\n\nrisk of major adverse cardiovascular events and\n\nHbA1c and\n\nweight. [...] evidence they had from a pooled analysis\n\ntheir ow", "score": 0.31264326 }, { "number": 23, "title": "6. Glycemic Goals and Hypoglycemia: Standards of Care in ...", "detail": "www.ccjm.org", "url": "https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc25-S006&link_type=DOI", "authors": "www.ccjm.org", "host": "www.ccjm.org", "snippet": "1990\n\n;\n\n8\n\n:\n\n267\n\n–\n\n272\n\nGoogle Scholar\n\nPubMed\n\n130.\n\nPhillip\n\nM\n\n, \n\nNimri\n\nR\n\n, \n\nBergenstal\n\nRM\n\n, _et al_. \n\nConsensus recommendations for the use of automated insulin delivery technologies in clinical practice\n\n. \n\nEndocr Rev\n\n2023\n\n;\n\n44\n\n:\n\n254\n\n–\n\n280\n\nGoogle Scholar\n\nCrossref\n\nSearch AD", "score": 0.2541529 }, { "number": 24, "title": "Tests for Screening and Diagnosis of Type 2 Diabetes", "detail": "diabetesjournals.org", "url": "https://diabetesjournals.org/clinical/article/27/4/132/1673/Tests-for-Screening-and-Diagnosis-of-Type-2", "authors": "diabetesjournals.org", "host": "diabetesjournals.org", "snippet": "The commonly held RPG threshold is ≥ 200 mg/dl, along with symptoms of polyuria, polydipsia, and unexplained weight loss to indicate a second", "score": 0.7869018 } ], "publishedAt": "2026-08-21T00:07:13.602801Z", "updatedAt": "2026-08-21T00:07:13.602801Z", "readingMinutes": 6, "slug": "type-2-diabetes" }